Drug Patents owned by Impax Labs Inc
1. List of Rytary drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7094427 | IMPAX LABS INC | Combination immediate release controlled release levodopa/carbidopa dosage forms |
May, 2022
(8 months ago) | |
| US8377474 | IMPAX LABS INC | Controlled release formulations of levodopa and uses thereof |
Dec, 2028
(5 years from now) | |
| US8454998 | IMPAX LABS INC | Controlled release formulations of levodopa and uses thereof |
Dec, 2028
(5 years from now) | |
| US8557283 | IMPAX LABS INC | Controlled release formulations of levodopa and uses thereof |
Dec, 2028
(5 years from now) | |
| US9901640 | IMPAX LABS INC | Controlled release formulations of levodopa and uses thereof |
Dec, 2028
(5 years from now) | |
| US9533046 | IMPAX LABS INC | Controlled release formulations of levodopa and uses thereof |
Dec, 2028
(5 years from now) | |
| US9463246 | IMPAX LABS INC | Controlled release formulations of levodopa and uses thereof |
Dec, 2028
(5 years from now) | |
| US9089607 | IMPAX LABS INC | Controlled release formulations of levodopa and uses thereof |
Dec, 2028
(5 years from now) | |
| US9089608 | IMPAX LABS INC | Controlled release formulations of levodopa and uses thereof |
Dec, 2028
(5 years from now) | |
Drugs and Companies using CARBIDOPA; LEVODOPA ingredient
Market Authorisation Date: 07 January, 2015
Treatment: Treatment of parkinson's disease, post-encephalitic parkinsonism, and parkinsonism that may follow carbon monoxide intoxication or manganese intoxication; Treatment of parkinson's disease; Treatment of post-encephalitic parkinsonism; Treatment of post-encephalitic parkinsonism, and parkinsonism that may follow carbon monoxide intoxication or manganese intoxication; Treatment of parkinsonism that may follow carbon monoxide intoxication or manganese intoxication; Method of providing a therapeutically effective and stable median blood plasma level of levodopa
Dosage: CAPSULE, EXTENDED RELEASE;ORAL
RYTARY family patents
20
United States
4
Israel
4
Japan
3
Korea, Republic of
3
European Union
2
Australia
2
Spain
2
Canada
2
New Zealand
2
Taiwan, Province of China
1
Hong Kong
1
South Africa
1
Mexico
1
China
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic